ClinicalTrials.gg
RecruitingNCT05761860Updated Nov 20, 2026

The Potential of Oxytocin to Reduce Opioid Abuse Liability and Pain Among Older Adults

An Early Phase 1 interventional study of OxyCODONE 5 mg Oral Tablet and OxyCODONE 2.5 mg Oral Tablet in Pain, sponsored by University of Florida. Recruiting at 1 site in United States. Open to participants aged 45 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by University of Florida · Early Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.
Updated Nov 20, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
45 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies testing oxycodone in Pain — 4 open to participants now, 5 under way, 1 of them phase 3. Oxycodone · Pain.

Planned enrollment
28th of 50
45 · median 67
Started
2023
with 2 others
Phase 1
10 of 50
2 open now
Registered
47th of 50
by date
Lead sponsor
2 of 50
University of Florida

Among the 50 studies testing oxycodone in Pain, this one is the 28th largest by planned enrollment, is one of 3 that started in 2023, is one of 10 in phase 1, and was the 47th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

4 of the 50 studies testing oxycodone in Pain are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About oxycodone

Oxycodone: first FDA approval 1950 (PERCODAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 45 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing oxycodone in Pain, or all of them as a file.
02

Study summary

Some research suggests that administration of oxytocin with oxycodone may reduce its abuse liability and improve its ability to reduce pain. In a 6-session laboratory study, we will be evaluating the effects of oxycodone and oxytocin (combined and separately, across sessions) on experimentally-induced pain, subjective effects, and decision-making.

Read the detailed description

The overall project goals are to determine oxytocin effects on oxycodone's subject-rated abuse liability, and experimental pain. Generally healthy individuals (determined via medical history review and a screening session) will, after informed consent, self-administer intranasal oxytocin (or placebo, containing the same ingredients but no oxytocin) shortly after oral oxycodone or placebo in a non-residential, double-blind, randomized, placebo-controlled, within-subjects laboratory study. Prescreening will assure drug application safety and, using a validated, comprehensive pain history interview, determine previous or existing chronic pain conditions, including current pain medication use.

03

Conditions studied

  • Pain

Browse trials for

Keywords

  • Pain
  • Abuse liability
04

Who can participate

Ages eligible
45 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals fluent in English will participate.
  • Must report some experience with opioids (e.g., oxycodone, defined as use at least once in the subject's lifetime).
  • Be within 20% of their ideal body weight.
  • Are not currently experiencing chronic pain (pain on most days during the past 3 months)
  • Have a systolic blood pressure of \<=140 and diastolic blood pressure of \<= 90, and a heart rate \<= 90 beats per minute.
  • Participants must also have a normal (EKG) reading and bloodwork indicating no major health .

Exclusion criteria

Exclusion Criteria:

  • Significant current physical disease or major (uncontrolled) psychiatric disorder.
  • No self-reported current interest in drug abuse treatment.
  • Women who are pregnant or nursing.
  • Any severe comorbid illicit substance use disorders or current withdrawal for any abused drug excluding nicotine and caffeine.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
45 participants (estimated)

Study arms

  • Active comparator
    Oral oxycodone (5mg) + intranasal oxytocin (48 IU)

    Combined effects of oxycodone and oxytocin.

    Drug: OxyCODONE 5 mg Oral Tablet · Drug: Oxytocin Nasal Spray (48 IU)

  • Active comparator
    Oral oxycodone (2.5mg) + intranasal oxytocin (48 IU)

    Combined effects of oxycodone and oxytocin.

    Drug: OxyCODONE 2.5 mg Oral Tablet · Drug: Oxytocin Nasal Spray (48 IU)

  • Active comparator
    Oral placebo + intranasal oxytocin (48 IU)

    Separate effects of oxytocin. As is standard methodology in abuse liability and pain assessments, a placebo condition will be included for each drug in order to compare the abuse liability and pain assessments change from placebo.

    Other: Placebo oxyCODONE Oral Tablet · Drug: Oxytocin Nasal Spray (48 IU)

  • Active comparator
    Oral oxycodone (5mg) + intranasal placebo

    Separate effects of oxycodone. As is standard methodology in abuse liability and pain assessments, a placebo condition will be included for each drug in order to compare the abuse liability and pain assessments change from placebo.

    Drug: OxyCODONE 5 mg Oral Tablet · Other: Placebo Oxytocin Nasal Spray

  • Active comparator
    Oral oxycodone (2.5mg) + intranasal placebo

    Separate effects of oxycodone. As is standard methodology in abuse liability and pain assessments, a placebo condition will be included for each drug in order to compare the abuse liability and pain assessments change from placebo.

    Drug: OxyCODONE 2.5 mg Oral Tablet · Other: Placebo Oxytocin Nasal Spray

  • Sham comparator
    Oral placebo + intranasal placebo

    Serves as the control.

    Other: Placebo oxyCODONE Oral Tablet · Other: Placebo Oxytocin Nasal Spray

Interventions

  • DrugOxycodoneStudies of OxycodoneOxycodone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oxycodone 5mg oral administration

  • DrugOxycodoneStudies of OxycodoneOxycodone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oxycodone 2.5mg oral administration

  • OtherPlacebo oxyCODONE Oral Tablet

    Oxycodone 0mg (placebo) oral administration

  • DrugOxytocinStudies of OxytocinOxytocin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intranasal oxytocin administration (48 IU)

  • OtherPlacebo Oxytocin Nasal Spray

    Intranasal oxytocin placebo administration

06

What researchers measure

Primary outcomes

  1. Subject-rated abuse liability

    Using a Visual Analog Scale with scoring as 0=not at all, 20=possibly mild, 40=definitely mild, 60=moderately, 80=strongly, and 100=extremely, or any number in between. Testing occurs only in the context of 6 sessions due to a minimum of a one week washout period in between each session.

    Time frame: Up to 6 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Sep 2027, 48 months after the start.

Of 118 non-industry phase 1 interventional studies under Pain, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's planned 48 months is above that.

Counting every sponsor, half of 222 studies reached it within 9 months; a quarter within 3 and three quarters within 29.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Dec 2026 → Sep 2027 and completion Jul 2027 → Apr 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2023
First posted
Mar 9, 2023
StartActual
Sep 12, 2023
Primary completionEst.
Sep 2027was Dec 2026
CompletionEst.
Apr 2028was Jul 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2026→Sep 2027
Nov 20, 2026
Study completion
Jul 2027→Apr 2028
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Primary completion Dec 2026→Sep 2027
    Study completion Jul 2027→Apr 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05761860
Responsible party
Sponsor
First posted
Mar 9, 2023
Start date
Sep 12, 2023
Primary completion
Sep 2027 (estimated)
Completion
Apr 2028 (estimated)
Last update
Nov 20, 2026

Study contacts

Lauren E Nieder, MSPH
Contact
lauren.nieder@ufl.edu
(352) 294-1067
Meredith S Berry, PhD
principal investigator · University of Florida

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Oxycodone · Oxytocin

Start the discussion